Revelation Biosciences announces accelerated Gemini development plan and strategic partnership initiatives
REVB•Revelation Biosciences plans to begin a Phase 2a study of Gemini in acute kidney injury in early 2027, with topline data expected that year. The study is expected to cost $7 million, down from a previous estimate of $60 million.
1. Study plans
Revelation Biosciences said it plans to initiate a Phase 2a study of Gemini in acute kidney injury in early 2027 and expects topline data in 2027. The study is expected to cost $7 million, compared with $60 million previously.




